Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSV-TK transduced donor lymphocytes (AP-HP)
- Development stage
- Unknown
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
HSV-TK transduced donor lymphocytes (AP-HP) is an investigational cell and gene therapy developed by Assistance Publique - Hôpitaux de Paris for the treatment of relapsed hematological malignancies following allogeneic hematopoietic stem cell transplantation (HSCT). The therapy involves the infusion of donor T-cells genetically modified to express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) suicide gene. This approach aims to harness the graft-versus-tumor (GVT) effect of donor lymphocytes to treat relapse and improve immune reconstitution. A critical safety feature of this therapy is the ability to control graft-versus-host disease (GVHD); if GVHD occurs, the administration of ganciclovir (GCV) triggers the selective elimination of the transduced T-cells, as the HSV-TK enzyme converts the prodrug ganciclovir into a cytotoxic metabolite that terminates the dividing alloreactive cells.
- Other names
- Suicide gene therapy for donor lymphocytes infusionHSV-TK modified T-cellsTK-transduced donor lymphocytes
02
Targets
HSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))
Beyond the preview
Go deeper on HSV-TK transduced donor lymphocytes (AP-HP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSV-TK transduced donor lymphocytes (AP-HP).